In the past four years, several papers assessed the diagnostic performance of PET imaging with PSMA-targeting radiopharmaceuticals to detect HCC lesions in newly diagnosed patients as well as in patients previously submitted to various lines of local or systemic therapy [28,29,30,31,32,33]. Here, FOLH1 is linked to hepatocellular carcinoma.